Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-08
2011-03-08
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
07902160
ABSTRACT:
Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
REFERENCES:
patent: 6653467 (2003-11-01), Matsuo et al.
patent: 2001/0056077 (2001-12-01), Matsuo et al.
patent: 2002/0055481 (2002-05-01), Matsuo et al.
patent: 1 054 058 (2000-11-01), None
patent: 1 054 058 (2000-11-01), None
patent: 1 152 009 (2001-11-01), None
patent: 1 160 318 (2001-12-01), None
patent: 1 191 098 (2002-03-01), None
patent: 2000-297097 (2000-10-01), None
patent: 2000-325085 (2000-11-01), None
patent: 2002-10790 (2002-01-01), None
patent: 2002-325582 (2002-11-01), None
patent: 00/47599 (2000-08-01), None
patent: WO 01/36443 (2001-05-01), None
patent: WO 02/024906 (2002-03-01), None
patent: WO 2004/083432 (2004-09-01), None
patent: WO 2004/083446 (2004-09-01), None
Matsuo (Brain and Dev. 18: 167-172, 1996).
Wahlestedt et al (Proc. Nat. Acad. Sci. USA (May 9, 2000) vol. 97, No. 10, pp. 5633-5638).
van Deutekom et al (Hum. Mol. Gen. 10(15): 1547-1554, 2001).
Van Vliet et al (BMC Med. Gen. 9:105, 2008).
Alter et al (Nat. Med. 12(2): 175-178, 2006).
Wilton et al (Neurology India 56(3): 254-262, 2008).
Crooke (In Basic Principles of Antisense Therapeutics, Springer-Verlag, Eds, New York, 1998, pp. 1-50).
Ho and Parkinson (Sem. Drug Discov. 24(2): 187-202, 1997).
Gryzanov (Biochim. Biophys. Acta 1489:131-140, 1999).
Agrawal et al. (Mol. Med. Today 6:72-81, 2000).
Opalinska et al (Nature Reviews Drug Discovery, 2002, vol. 1, pp. 503-514).
Scanlon (Curr. Pharm. Biotech. 5:415-420, 2004).
Verreault et al (Curr. Gene Ther. 6: 505-533, 2006).
Yokota et al (Ann. Neurol. 65: 667-676, 2009).
Mann et al (PNAS 98(1): 42-47, 2001).
Gebski et al (Hum. Mol. Gen. 12(15): 1801-1811, 2003).
Lu et al (Nature Medicine 9(8) 1009-1014, 2003).
Bremmer-Bout (Mol. Ther. 10(2): 232-240, 2004).
Pramono, Zacharias Aloysius et al.: “Introduction of Exon Skipping of the Dystrophin Transcript in Lymphoblastoid Cells by Transfecting an Antisense Oligodeoxynudeotide Complementary to an Exon Recognition Sequence” Biochemical and Biophysical Research Communications, vol. 226, No. 2, pp. 445-449, 1996.
Nobuyuki Shiga et al.: “Disruption of the Splicing Enhancer Sequence within Exon 27 of the Dystrophin Gene by a Nonsense Mutation Induces Partial Skipping of the Exon and Is Responsible for Becker Muscular Dystrophy”, J. Clin. Invest., vol. 100, No. 9, pp. 2204-2210, Nov. 1997.
Agus Surono et al.: “Six Novel Transcripts That Remove a huge Intron Ranging from 250 to 800 kb Are Produced by Alternative Splicing of the 5′ Region of the Dystrophin Gene in Human Skeletal Muscle”, Biochemical and Biophysical Research Communications, vol. 239, No. 3, pp. 895-899, 1997.
Agus Surono et al.: “Circular dystrophin RNAs consisting of exons that were skipped by alternative splicing”, Human Molecular Genetics, vol. 8, No. 3, pp. 493-500, 1999.
Zacharias Aloysius Dwi Pramono et al.: “A Novel Cryptic Exon in Intron 2 of the Human Dystrophin Gene Evolved from an Intron by Acquiring Consensus Sequences for Splicing at Different Stages of Anthropoid Evolution”, Biochemical and Biophysical Research Communications, vol. 267, No. 1, pp. 321-328, 2000.
Chieko Ishigaki et al.: Early cardiac failure in a child with Becker muscular dystrophy is due to an abnormally low amount of dystrophin transcript lacking exon 13, Acta Paediatrica Japonica, vol. 39, pp. 685-689, 1997.
Masanori INO-UE et al.: “Genotype and Electroretinal Heterogeneity in Duchenne Muscular Dystrophy”, Exp. Eye Res., vol. 65, pp. 861-864, 1997.
N. Tachi et al.: “Deficiency of syntrophin, dystroglycan, and merosin in a female infant with a congenital muscular dystrophy phenotype lacking cysteine-rich and C-terminal domains of dystrophin”, Neurology. vol. 49, pp. 579-583, 1997.
Nobuyukl Shiga et al.: “Study on Mutations Affecting the Muscle Promoter/First Exon of the Dystrophin Gene in 92 Japanese Dilated Cardiomyopathy Patients”, American Journal of Medical Genetics, vol. 79, pp. 226-227, 1998.
D-H. Chen et al.: “A novel deletion of the dystrophin S-promoter region cosegregating with metal”, Neurology. vol. 52, pp. 638-640, 1999.
Suryono Yudha Patria et al.: “A simple explanation for a case of incompatibility with the reading frame theory in Duchenne muscular dystrophy: failure to detect an aberrant restriction fragment in Southern blot analysis”, Brain & Development, vol. 21, pp. 386-389, 1999.
Yasuhlro Takeshima et al.: “Molecular genetics and problems found in genetic diagnosis of Duchenne/Becker muscular dystrophy”, Nihon Rinsho, vol. 55, No. 12, pp. 3120-3125, 1997.
Masafumi Matsuo et al.: “Gene Diagnosis in the Field of Child Neurology: Introductory Remarks”, No To Hattatsu, vol. 30, pp. 121-122, 1998.
Matsuo, M, “Duchenne and Becker Muscular Dystrophy: From Gene Diagnosis to Molecular Therapy,” Life, vol. 53, 2002, pp. 147-152, XP009021242.
Takshima, Y., et al., “Oligonucleotides Against a Splicing Enhancer Sequence Led to Dystrophin Production in Muscle Cells from a Duchenne Muscular Dystrophy Patient,” Brain & Development, vol. 23, 2001, pp. 788-790, XP009101406.
Mann, C. J., et al., “Improved Antisense Oligonucleotide Induced Exon Skipping in the MDX Mouse Model of Muscular Dystrophy,” The Journal of Gene Medicine, vol, 4, 2002, pp. 644-654, XP009015057.
Van Deutekom, J., et al., “Antisense-Induced Exon Skipping Restores Dystrophin Expression in DMD Patient Derived Muscle Cells,” Human Molecular Genetics, vol. 10, No. 15, 2001, pp. 1547-1554, XP-002250908.
Surono, A., et al., “Chimeric RNA/Ethylene-Bridged Nucleic Acids Promote Dystrophin Expression in Myocytes of Duchenne Muscular Dystrophy by Inducing Skipping of the Nonsense Mutation-Encoding Exon,” Human Gene Therapy, vol. 15, Aug. 2004, pp. 749-757, XP009101403.
Harding, PL, et al., “The Influence of Antisense Oligonucleotide Length on Dystrophin Exon Skipping,” Molecular Therapy, vol. 15, No. 1, Jan. 2007, pp. 157-166, XP009101408.
Takeshima, et al., Intravenous Infusion of an Antisense Oligonucleotide Results in Exon Skipping in Muscle Dystrophin mRNA of Duchenne Muscular Dystrophy, Pediatric Research, vol. 59, No. 5, 2006, pp. 690-694.
Scheuerbrandt, “Research Approaches for a Therapy of Duchenne Muscular Dystrophy”, Parent Project Muscular Dystrophy, action duchenne, TREAT-NMD, pp. 1-20, Apr. 30, 2009, http://www.cureduchenne.org/2009/05/research-approaches-for-a-therapy-of-duchenne-muscular-dystrophy/.
Beroud, et al., “Multiexon Skipping Leading to an Artifical DMD Protein Lacking Amino Acids from Exons 45 Through 55 Could Rescue Up to 63% of Patients With Duchenne Muscular Dystrophy”, Human Mutation, 28(2), pp. 196-202, 2007.
van Deutekom, “Local Dystrophin Restoration with Antisense Oligonucleotide PRO051”, The New England Journal of Medicine, vol. 357; 26, pp. 2677-2686, 2007.
Annemieke AARTSMA-RUS, et al., “Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy”, Neuromuscular Disorders 12 (2002) S71-S77.
Koji Morita, et al., 2'-O,4'-C-Ethylene-Bridged Nucleic Acids (ENA): Highly Nuclease-Resistant and Thermodynamically Stable Oligonucleotides for Antisense Drug, Bioorganic & Medicinal Chemistry Letters, vol. 12, No. 1 (Jan. 2002), p. 73-76.
Christopher J. Mann, et al., “Antisense-induced exon skipping and synthesis of dystrophin in themdxmouse”, PNAS, vol. 98, No. 1 (2001), p. 42-47.
Fernada Gabriella de Angelis, et al., “Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthes
Koizumi Makoto
Matsuo Masafumi
Takeshima Yasuhiro
KNC Laboratories Co., Ltd.
Matsuo Masafumi
Nonprofit Organization Translational Research Organization of Du
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Schnizer Richard
LandOfFree
ENA nucleic acid drugs modifying splicing in mRNA precursor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ENA nucleic acid drugs modifying splicing in mRNA precursor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ENA nucleic acid drugs modifying splicing in mRNA precursor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2773059